Earnings summaries and quarterly performance for Galera Therapeutics.
Executive leadership at Galera Therapeutics.
Board of directors at Galera Therapeutics.
Research analysts covering Galera Therapeutics.
Recent press releases and 8-K filings for GRTX.
Galera Therapeutics announces sale of dismutase mimetics portfolio to Biossil
GRTX
M&A
New Projects/Investments
- Galera Therapeutics has entered into an Asset Purchase Agreement with Toronto-based Biossil Inc. for its dismutase mimetics portfolio, including avasopasem and rucosopasem.
- The agreement includes an upfront payment of $3.5 million and potential future regulatory and commercial milestones, and contingent value rights of up to $105 million in aggregate.
- Biossil will assume all obligations for a 4% royalty to Blackstone Life Sciences should the dismutase mimetics products reach commercialization.
- Following this transaction, Galera's lead program will be its pan-inhibitor of Nitric Oxide Synthase (NOS), currently in a multicenter Phase 2 trial for metaplastic breast cancer.
- Avasopasem, part of the acquired portfolio, had previously received FDA Fast Track and Breakthrough Therapy designations and showed a statistically significant reduction in severe oral mucositis in a Phase 3 trial.
Oct 22, 2025, 11:00 AM
Ask Fintool AI Agent
Get instant answers from SEC filings, earnings calls & more